Human Gene Sequencing Markets 2027–2031

Human Gene Sequencing Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027–2031

Global forecasts by application, technology, workflow, customer and product, for 14 countries and regions, with 55 company profiles.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

Human gene sequencing is now a clinical business. Cancer and prenatal laboratories are growing at rates rarely seen in diagnostics, large buyers are consolidating the industry, and the main risk has moved from the FDA to Medicare. The market grows from $13,450 million in 2026 to $30,100 million in 2031, at 17.5% a year. Long reads nearly double their share, but routine whole genome sequencing of healthy people is still at least five years away.

Market Size 2026: USD $13.45B Market Size 2031: USD $30.1B CAGR: 17.5%

Situation Analysis: what is really happening

• Clinical labs are growing fast. Natera, Guardant, Caris and BillionToOne reported growth of 38% to 64% in the second quarter of 2026.
• Large buyers are consolidating. Abbott completed its roughly $21 billion purchase of Exact Sciences, Tempus agreed to buy Personalis for about $1.5 billion, and EQT made an offer to take Qiagen private.
• Regulators approve larger tests. The FDA approved Guardant360 Liquid CDx, and an FDA panel voted in favour of Grail's Galleri multi-cancer test.
• Medicare is the main risk. CMS's preliminary 2027 rates cut genomic sequencing codes by about 23% before a 15% annual cap.
• Long reads double their share. Long-read sequencing grows 32.3% a year, from 10.5% to 19% of the market.
• Clinical labs take the lead. Clinical laboratories and hospitals rise from 40.5% to 47.5% of spending, and oncology adds the most new dollars.

Company Analysis: who is positioned, who is exposed

• Illumina: Keeps the largest installed base and raised its 2026 guidance on clinical demand.
• Element, Ultima, Roche, PacBio and Oxford Nanopore: New short-read and long-read platforms push down the cost per sample.
• Natera, Guardant and Caris: Fast-growing oncology and prenatal laboratories.
• Abbott (Exact Sciences) and Tempus: Buyers consolidating cancer testing.
• Myriad and GeneDx: Show how payer pressure can cut price per test faster than volume grows.

In all, 55 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Questions this report answers

• How fast will oncology, prenatal and hereditary sequencing grow?
• What will Medicare's 2027 to 2029 rate cuts do to laboratory economics?
• How fast will long-read platforms take share from short-read NGS?
• When will whole genome sequencing become routine care?
• Who are the leading platform makers and laboratories, and who is buying whom?
• How large is each country market, and how fast is China growing?

What's inside

• 316 pages, 23 chapters, 64 tables and 52 figures
• Forecasts for 2027–2031 from a 2026 base year, by application, technology, workflow, customer and product, for 14 countries and regions
• Hereditary, psychiatric and neurological testing, reproductive genetics and NIPT, and oncology sequencing
• Technology and workflow, data analysis and AI, regulation and reimbursement, and whole genome, pharma, research and consumer markets
• 10 market-moving developments from 2025 and 2026, SWOT, Porter's Five Forces and strategic recommendations
• 55 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Sequencing platform and reagent companies: plan products and pricing for a market led by clinical laboratories.
• Laboratory executives and business development teams: size oncology, prenatal and hereditary opportunities and judge payment risk.
• Investors and analysts: assess growth, consolidation and Medicare exposure.
• Pharma and health systems: plan sequencing for drug development and clinical care.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.Sc., M.B.A., is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.